We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Black Diamond Therapeutics Inc (BDTX) USD0.0001

Sell:$4.89 Buy:$4.90 Change: $0.17 (3.34%)
NASDAQ:0.51%
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$4.89
Buy:$4.90
Change: $0.17 (3.34%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$4.89
Buy:$4.90
Change: $0.17 (3.34%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Contact details

Address:
One Main Street, 14Th Floor
CAMBRIDGE
02142
United States
Telephone:
+1 (617) 4175868
Website:
https://www.blackdiamondtherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BDTX
ISIN:
US09203E1055
Market cap:
$263.24 million
Shares in issue:
51.72 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Mark Velleca
    Chairman of the Board, President, Chief Executive Officer
  • Elizabeth Buck
    Co-Founder, Chief Scientific Officer
  • Fang Ni
    Chief Financial Officer, Chief Business Officer
  • Brent Hatzis-Schoch
    Chief Operating Officer, General Counsel
  • Elizabeth Montgomery
    Chief People Officer
  • Erika Jones
    Vice President - Finance, Corporate Controller
  • Sergey Yurasov
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.